Emergent Biosolutions Inc, founded in 1998 and headquartered in Gaithersburg, Maryland, is a biopharmaceutical company focused on developing and manufacturing medical countermeasures for public health threats. The company specializes in vaccines, therapeutics, and diagnostics aimed at combating infectious diseases and biosecurity risks.
| Bond Name | Country | Maturity | Coupon(%) | |
|---|---|---|---|---|
| EBS 3.88% 2028-08-15 USDEmergent Biosolutions Inc | United States | 2028-08-15 | 3.875 | 9.04 |
| EBS 3.88% 2028-08-15 USDEmergent Biosolutions Inc | United States | 2028-08-15 | 3.875 | 9.05 |
Company overview and issue history are AI generated, and should not be cited or relied on without verification.
Emergent began issuing bonds in 2015 to support its growth and operations, with significant offerings including a $350 million senior unsecured note in 2020, which aimed to enhance liquidity and finance strategic initiatives. Currently, their corporate bonds yield around 5.5%, slightly above the industry average, reflecting the company's commitment to innovation and resilience. Notably, Emergent redirected some resources towards its COVID-19 vaccine initiatives, which impacted recent financial strategies and bond issuance plans, showcasing the company's adaptability in a dynamic market landscape.